Boehringer Ingelheim Selects Certara's D360 as its Global Drug Discovery Platform

Boehringer Ingelheim Selects Certara's D360 as its Global Drug Discovery Platform

D360™ will permit chemical structure and related biological property data to be shared between global sites.

ST. LOUIS, MO – Oct. 17, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that the pharmaceutical company Boehringer Ingelheim has chosen D360 as its global drug discovery platform. Certara's D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. D360 will allow Boehringer Ingelheim to share discovery data across global working groups that can include external collaborators.
Boehringer Ingelheim plans to install the global data mining tool at three of its sites, located in Ridgefield, CT; Biberach, Germany; and Vienna, Austria. All of the sites are currently using different data sources, mining tools, and workflows for analyzing the information.
"In addition to integrating data for easy access, D360 empowers researchers to query and analyze their data without support from the IT team," said Jonathan Feldmann, vice president of scientific informatics at Certara. "D360 enables researchers to quickly answer their questions as they conceive them, thus helping to shorten the drug discovery cycle."
About Certara
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit
Certara Contact: 
Diana O'Rourke, 314-951-3310
Director of Marketing
Media Contact: 
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.